Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Network for Genomic Surveillance in South Africa, Cele, Sandile, COMMIT-KZN Team, Gazy, Inbal, Jackson, Laurelle, Hwa, Shi-Hsia, Tegally, Houriiyah, Lustig, Gila +15 more·2021·Nature
DOI 10.1038/s41586-021-03471-w

Cited by (658)

Items 401–500 of 658

  1. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
    Aljawharah Alrubayyi, Ester Gea‐Mallorquí, Emma Touizer, Dan Hameiri‐Bowen, Jakub T. Kopycinski, Bethany G. Charlton, Natasha Fisher-Pearson, Luke Muir, Annachiara Rosa, Chloë Roustan et al. · 2021 · Research Square
  2. Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19
    Shunyao Chen, Cong Zhang, Deng Chen, Liming Dong, Teding Chang, Zhaohui Tang · 2023 · Frontiers in Immunology
  3. Dynamics of spike-specific neutralizing antibodies across five-year emerging SARS-CoV-2 variants of concern reveal conserved epitopes that protect against severe COVID-19
    Latifa Zayou, Swayam Prakash, Hawa Vahed, Nisha Rajeswari Dhanushkodi, Afshana Quadiri, Ahmed Belmouden, Zohra Lemkhente, Aziz Alami Chentoufi, Daniel Gil, Jeffrey B. Ulmer et al. · 2025 · Frontiers in Immunology
  4. Optimal Timing of Vaccination: A Narrative Review of Integrating Strategies for COVID-19, Influenza, and Respiratory Syncytial Virus
    Paolo Bonanni, Jung Yeon Heo, Hitoshi Honda, Ping‐Ing Lee, Aminatou Mouliom, Hoe Nam Leong, Maria del Pilar Martin Matos, Rachel Souza Dawson · 2025 · Infectious Diseases and Therapy
  5. Mild Symptomatic SARS-CoV-2 P.1 (B.1.1.28) Infection in a Fully Vaccinated 83-Year-Old Man
    Marco Fabiani, Katia Margiotti, Antonella Viola, Alvaro Mesoraca, Claudio Giorlandino · 2021 · Pathogens
  6. Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets
    Shane Riddell, Sarah Goldie, Alexander J. McAuley, Michael J. Kuiper, Peter A. Durr, Kim R. Blasdell, Mary Tachedjian, Julian D Druce, Trevor R.F. Smith, Kate E. Broderick et al. · 2021 · Frontiers in Immunology
  7. Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals
    Joanna Luczkowiak, Nuria Labiod, Gonzalo Alonso Rivas, Marta Rolo, Fátima Lasala, Jaime Lora‐Tamayo, Mikel Mancheño‐Losa, David Rial, Alfredo Pérez‐Rivilla, María Dolores Folgueira et al. · 2021 · Open Forum Infectious Diseases
  8. Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants
    Marianna Agudelo, Frauke Muecksch, Dennis J. Schaefer-Babajew, Alice Cho, Justin DaSilva, Eva Bednarski, Victor A. Ramos, T. Oliveira, M. Cipolla, A. Gazumyan et al. · 2022 · Journal of Experimental Medicine
  9. A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients
    Solat Eslami, Mark Charles Glassy, Soudeh Ghafouri‐Fard · 2021 · Gene
  10. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice
    Longbo Hu, Yuhua Xu, Liping Wu, Jin Feng, Lu Zhang, Yongjie Tang, Xiang Zhao, Runming Mai, Liyun Chen, Lingling Mei et al. · 2022 · Viruses
  11. Convolutional Neural Networks Based on Sequential Spike Predict the High Human Adaptation of SARS-CoV-2 Omicron Variants
    Bei-Guang Nan, Sen Zhang, Yuchang Li, Xiaoping Kang, Yuehong Chen, Lin Li, Tao Jiang, Jing Li · 2022 · Viruses
  12. The importance of combining serological testing with RT-PCR assays for efficient detection of COVID-19 and higher diagnostic accuracy
    Sawsan S. Alamri, Ahdab Alsaieedi, Yousef Khouqeer, Marwah A. Afeef, Samiyah O. Alharbi, Abdullah A. Algaissi, Maimonah S. Alghanmi, Tarfa A. Altorki, Ayat Zawawi, Mohamed A. Alfaleh et al. · 2023 · PeerJ
  13. Water-soluble tocopherol derivatives inhibit SARS-CoV-2 RNA-dependent RNA polymerase
    Hayden T. Pacl, Jennifer L. Tipper, Ritesh Rajesh Sevalkar, Andrew B. Crouse, Camerron M. Crowder, Shama Ahmad, Aftab M. Ahmad, Gillian D. Holder, Charles J. Kuhlman, Krishna C. Chinta et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  14. An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity
    Emma Chang-Rabley, Menno C. van Zelm, Emily Ricotta, Emily S.J. Edwards · 2024 · Vaccines
  15. In vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential
    Brandon Krishna Lam, Yu Jui Kung, John W Lin, Ssu-Hsueh Tseng, Ya Chea Tsai, Liangmei He, Gianni M. Castiglione, Emily R. Egbert, Elia J. Duh, Evan M. Bloch et al. · 2021 · Cell Reports
  16. Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout
    Sabine Lichtenegger, Sabine Saiger, Melina Hardt, Susanne Kulnik, Gabriel E. Wagner, Barbara Kleinhappl, Karoline Assig, Andrea Zauner, Michelle Ober, Janine Kimpel et al. · 2022 · Journal of Clinical Microbiology
  17. Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants
    Masayuki Amano, Sachiko Otsu, Kenji Maeda, Yukari Uemura, Yosuke Shimizu, Kazumi Omata, Masao Matsuoka, Shinya Shimada, Hiroaki Mitsuya · 2022 · Scientific Reports
  18. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
    Maheshi Ramasamy, Elizabeth J. Kelly, Seth Seegobin, Paul Ivor Dargan, Ruth Payne, Vincenzo Libri, Matthew Adam, Parvinder K. Aley, Nuria Martinez-Alier, Alison Church et al. · 2023 · The Lancet Microbe
  19. Humoral and cellular immunity against diverse SARS-CoV-2 variants
    Changxu Chen, Xin Wang, Zeli Zhang · 2023 · Journal of genetics and genomics/Journal of Genetics and Genomics
  20. Characterization of SARS-CoV-2 replication in human H1299/ACE2 cells: A versatile and practical infection model for antiviral research and beyond
    Clarisse Salgado‐Benvindo, Ali Taş, Jessika C. Zevenhoven-Dobbe, Yvonne van der Meer, Igor A. Sidorov, Anouk A. Leijs, Patrick Wanningen, Anne T. Gelderloos, Puck B. van Kasteren, Eric J. Snijder et al. · 2024 · Antiviral Research
  21. Singular Interface Dynamics of the SARS-CoV-2 Delta Variant Explained with Contact Perturbation Analysis
    Aria Gheeraert, Laurent Vuillon, Laurent Chaloin, Olivier Moncorgé, Thibaut Véry, Serge Pérez, Vincent Leroux, Isaure Chauvot de Beauchêne, Dominique Mias‐Lucquin, Marie‐Dominique Devignes et al. · 2022 · Journal of Chemical Information and Modeling
  22. Structural basis of Omicron immune evasion: A comparative computational study
    Darshan Contractor, Christoph Globisch, Shiv Swaroop, Alok K. Jain · 2022 · Computers in Biology and Medicine
  23. Integrated lipidomic and proteomic profiling reveals metabolic network disruption by SARS-CoV-2 variants
    Scotland E. Farley, Jennifer E Kyle, Helene Jahn, Lisa Bramer, Paul Piehowski, Athena A Shepmoes, Brooke L. Deatherage Kaiser, Sarai M. Williams, Josie Eder, Carsten Schultz et al. · 2025 · Journal of Lipid Research
  24. Perspectives in the Emergence and Re-Emergence of Infectious Diseases, Geopolitics and Gain-of-Function Research
    Chrysanthus Chukwuma · 2022 · Scholars International Journal of Biochemistry
  25. Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection
    Mohammad A. I. Al-Hatamleh, Mai Abdel Haleem Abusalah, Ma’mon M. Hatmal, Walhan Alshaer, Suhana Ahmad, Manali Haniti Mohd-Zahid, Engku Nur Syafirah Engku Abd Rahman, Chan Yean Yean, Iskandar Zulkarnain Alias, Vuk Uskoković et al. · 2022 · Journal of Taibah University Medical Sciences
  26. Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development
    Stephen Boulton, Mathieu J. F. Crupi, Siddharth Singh, Madalina Elena Carter-Timofte, Taha Azad, Bailey C. Organ, Xiaohong He, Rida Gill, Serge Neault, Taylor R. Jamieson et al. · 2023 · Journal of Biological Chemistry
  27. Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time
    Ahmed M. Moustafa, Paul Joseph Planet · 2021 · Journal of the Pediatric Infectious Diseases Society
  28. Occurrence of a substitution or deletion of SARS-CoV-2 spike amino acid 677 in various lineages in Marseille, France
    Philippe Colson, Jérémy Delerce, Emilie Burel, Mamadou Beye, Pierre‐Edouard Fournier, Anthony Levasseur, Jean‐Christophe Lagier, Didier Raoult · 2021 · Virus Genes
  29. Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, Kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform
    Rajashree Patil, Sonali Hemant Palkar, Akhileshchandra Mishra, Rahul Patil, Vidya Avinash Arankalle · 2023 · Frontiers in Immunology
  30. Understanding the Potential Impact of Different Drug Properties on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission and Disease Burden: A Modelling Analysis
    Charles Whittaker, Oliver John Watson, Carlos Álvarez, Nasikarn Angkasekwinai, Adhiratha Boonyasiri, Luis Carlos Triana, Duncan M Chanda, Lantharita Charoenpong, Methee Chayakulkeeree, Graham Cooke et al. · 2021 · Clinical Infectious Diseases
  31. Naturally-acquired immunity in Syrian Golden Hamsters provides protection from re-exposure to emerging heterosubtypic SARS-CoV-2 variants B.1.1.7 and B.1.351
    Jordan J. Clark, Parul Sharma, Eleanor G. Bentley, Adam C. Harding, Anja Kipar, Megan Neary, Helen Box, Grant L. Hughes, Edward I. Patterson, Joanne Sharp et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  32. Amino acids 484 and 494 of SARS-CoV-2 spike are hotspots of immune evasion affecting antibody but not ACE2 binding
    Marta Alenquer, Filipe Ferreira, Diana Lousa, Mariana Valério, Mónica Medina-Lopes, Marie‐Louise Bergman, Juliana Gonçalves, Jocelyne Demengeot, Ricardo B. Leite, Jingtao Lilue et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  33. BNT162b2 Vaccination Efficacy is Marginally Affected by the SARS-CoV-2 B.1.351 Variant in Fully Vaccinated Individuals
    Orna Mor, Neta S. Zuckerman, Itay Hazan, Ronen Fluss, Nachman Ash, Netanel Ginish, Ella Mendelson, Sharon Alroy‐Preis, Laurence S. Freedman, Amit Huppert · 2021 · medRxiv
  34. SARS-CoV-2 humoral immunity in people living with HIV-1
    Boitumelo M. Motsoeneng, Jinal N. Bhiman, Simone I. Richardson, Penny L. Moore · 2024 · Trends in Immunology
  35. Novel Highly Divergent SARS-CoV-2 Lineage With the Spike Substitutions L249S and E484K
    Katherine Laiton‐Donato, José Aldemar Usme-Ciro, Carlos Franco-Muñoz, Diego Alejandro Álvarez-Díaz, Héctor Alejandro Ruiz-Moreno, Jhonnatan Reales-González, Diego Prada-Cardozo, Sheryll Corchuelo, María T. Herrera-Sepúlveda, Julián Naizaque et al. · 2021 · Frontiers in Medicine
  36. A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus
    Junzhi Wang · 2021 · Signal Transduction and Targeted Therapy
  37. Powered Respirators Are Effective, Sustainable, and Cost-Effective Personal Protective Equipment for SARS-CoV-2
    Alasdair Peter Stuart Munro, Jacqui A. Prieto, Emmanouil Mentzakis, Mohammed Dibas, Nitin Mahobia, Peter Baker, Sarah Herbert, Trevor Russell Smith, Matthew Hine, Joann Hall et al. · 2021 · Frontiers in Medical Technology
  38. Leveraging South African HIV research to define SARS‐CoV ‐2 immunity triggered by sequential variants of concern
    Jinal N. Bhiman, Penny L. Moore · 2022 · Immunological Reviews
  39. Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan
    Hidetoshi Igari, Haruna Asano, Shota Murata, Toshihiko Yoshida, Kenji Kawasaki, Takahiro Kageyama, Key Ikeda, Hiromi Koshikawa, Yoshio Okuda, Misao Urushihara et al. · 2022 · Journal of Infection and Chemotherapy
  40. S Trimer Derived from SARS-CoV-2 B.1.351 and B.1.618 Induced Effective Immune Response against Multiple SARS-CoV-2 Variants
    Hongye Wang, Zengshuai Wang, Liang Ma, Xiaoyong Zhu, Bingxiang Li, Yuhang Huang, Jingwen Li, Ming Sun, Li Shi, Yufeng Yao · 2023 · Vaccines
  41. Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population
    Sina Hosseinian, Rafael de Assis, Ghali Khalil, Madeleine K. Luu, Aarti Jain, Aarti Jain, Rie Nakajima, Anton M. Palma, Anton Palma, Eisa Razzak et al. · 2023 · Frontiers in Immunology
  42. Emerging anti-spike monoclonal antibodies against SARS-CoV-2
    Eloy E. Ordaya, Raymund Rabe Razonable · 2024 · Expert Opinion on Biological Therapy
  43. The Genomic Landscape of Severe Acute Respiratory Syndrome Coronavirus 2
    M. Shaheen Malick, Helen Fernandes · 2021 · Advances in Molecular Pathology
  44. Thermodynamics and kinetics in antibody resistance of the 501Y.V2 SARS-CoV-2 variant
    Sơn Tùng Ngô, Trung Hai Nguyen, Duc-Hung Pham, Nguyễn Thanh Tùng, Pham Cam Nam · 2021 · RSC Advances
  45. Rare COVID reactions might hold key to variant-proof vaccines
    Ewen Callaway · 2021 · Nature
  46. Characterization of SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.618 on cell entry, host range, and sensitivity to convalescent plasma and ACE2 decoy receptor
    Wenlin Ren, Xiaohui Ju, Mingli Gong, Jun Lan, Yanying Yu, Quanxin Long, Yu Long Zhang, Jin Zhong, Guocai Zhong, Xinquan Wang et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  47. Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV
    Khadija Khan, Gila Lustig, Mallory Bernstein, Derseree Archary, Sandile Cele, Farina Karim, Muneerah Smith, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy et al. · 2021 · medRxiv
  48. Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses
    Alexandra C. Walls, Kaitlin R. Sprouse, Anshu Joshi, John E. Bowen, Nicholas Franko, Mary Jane Navarro, Cameron Stewart, Matthew McCallum, Erin A. Goecker, Emily Degli-Angeli et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  49. Visible blue light inactivates SARS-CoV-2 variants and inhibits Delta replication in differentiated human airway epithelia
    Jacob Kocher, Leslee Arwood, Rachel C. Roberts, Ibrahim Henson, Abigail Annas, David Emerson, Nathan Stasko, M. Leslie Fulcher, Marisa Brotton, Scott H. Randell et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  50. SARS-CoV-2 evolves increased infection elicited cell death and fusion in an immunosuppressed individual
    Gila Lustig, Yashica Ganga, Hylton E. Rodel, Houriiyah Tegally, Laurelle Jackson, Sandile Cele, Karim Khan, Zesuliwe Jule, Kajal Reedoy, Farina Karim et al. · 2022 · medRxiv
  51. Development and application of an RT‒PCR assay for the identification of the delta and omicron variants of SARS-COV-2
    German Alexandrovich Shipulin, Yuliya A. Savochkina, Шуряева Анна Константиновна, E.E. Glushchenko, Andrey R. Luparev, V.A. Polyakova, DI Danilov, Давыдова Екатерина Евгеньевна, Kirill S. Vinogradov, И.Ф. Стеценко et al. · 2023 · Heliyon
  52. Development of Methods to Produce SARS CoV‐2 Virus‐Like Particles at Scale
    Melissa Anne Edeling, Linda Earnest, Julio Carrera Montoya, Ashley Huey Yiing Yap, Jamie Mumford, Jason Roberts, Chinn Yi Wong, Dhiraj Hans, Joseph Grima, Nicole Bisset et al. · 2025 · Biotechnology and Bioengineering
  53. No country or continent is on its own in the ongoing COVID-19 pandemic
    Kari Johansen, Hanna Nohynek · 2021 · Eurosurveillance
  54. Innovative vaccine approaches—a Keystone Symposia report
    Jennifer Cable, Rino Rappuoli, Elizabeth J. Klemm, Gagandeep Kang, Ankur Mutreja, Gavin James Wright, Mariagrazia Pizza, Sowmya Ajay Castro, Joseph P. Hoffmann, Galit Alter et al. · 2022 · Annals of the New York Academy of Sciences
  55. Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations?
    Akshay Kanakan, Priyanka Mehta, Priti Devi, Sheeba Saifi, Aparna Swaminathan, Ranjeet Maurya, Partha Chattopadhyay, Bansidhar Tarai, Poonam Das, Vinita Jha et al. · 2022 · Frontiers in Microbiology
  56. Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?
    Xuesong He, Xiao Xue Zeng · 2022 · Drug Design Development and Therapy
  57. Novel Lateral Flow-Based Assay for Simple and Visual Detection of SARS-CoV-2 Mutations
    Julien Gomez-Martinez, Steven Henry, Édouard Tuaillon, Philippe Van de Perre, Chantal Fournier‐Wirth, Vincent Foulongne, Jean-Charles Brès · 2022 · Frontiers in Cellular and Infection Microbiology
  58. Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern
    Gonzalo Almanza, A. Clark, V. Kouznetsova, Eduardo Olmedillas, Andrea Castro, I. Tsigelny, Yan Wu, G. Gao, S. Leibel, W. Bray et al. · 2022 · PLoS Pathogens
  59. Homologous or Heterologous COVID-19 Booster Regimens Significantly Impact Sero-Neutralization of SARS-CoV-2 Virus and Its Variants
    Rome Buathong, Taweewun Hunsawong, Supaporn Wacharapluesadee, Suriya Guharat, Ratthapat Jirapipatt, Sasiprapa Ninwattana, Nattakarn Thippamom, Anusara Jitsatja, Anthony R. Jones, Kamonthip Rungrojchareonkit et al. · 2022 · Vaccines
  60. Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern
    Steven Y. Gao, Nancy B. Amaro-Mugridge, Jocelyn Madrid-Weiss, Nikolina Petkovic, Natasha Vanegas, Kumar Visvanathan, Bryan R.G. Williams, Jennifer A. MacDiarmid, Himanshu N. Brahmbhatt · 2023 · Frontiers in Immunology
  61. A Protein Co-Conservation Network Model Characterizes Mutation Effects on SARS-CoV-2 Spike Protein
    Lianjie Zeng, Yitan Lu, Wenying Yan, Yang Yang · 2023 · International Journal of Molecular Sciences
  62. Ensovibep, a SARS‐CoV‐2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first‐in‐human, ascending single‐dose Phase 1 study
    Nina Stojcheva, Stacy J. Gladman, Marianne Soergel, Christof Zitt, Roxana F. Drake, Tony Lockett, Carine Marchand, Pierre Fustier, Vaia Stavropoulou, Elena Fernández et al. · 2023 · British Journal of Clinical Pharmacology
  63. Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant
    Tae-Hun Kim, Sojung Bae, Sunggeun Goo, Jinjong Myoung · 2023 · Journal of Microbiology and Biotechnology
  64. Quantifying the Impact of Lifting Community Nonpharmaceutical Interventions for COVID-19 During Vaccination Rollout in the United States
    Laura Matrajt, Holly Janes, Joshua Tisdell Schiffer, Dobromir Dimitrov · 2021 · Open Forum Infectious Diseases
  65. Reinfection and Breakthrough Infection of SARS-CoV-2: An Emerging Challenge That Is Threatening Our World
    Linbo Gao, Xiuying Mu, Yan‐Mei Jiao, Fu‐Sheng Wang · 2021 · Infectious Diseases & Immunity
  66. Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study
    Guillaume Louis, Thibaut Belveyre, Christophe Goetz, Sébastien Gibot, Paul Dunand, Marie Conrad, Rostane Gaci, Sébastien Gette, Nadia Ouamara, Pascale Perez et al. · 2022 · Frontiers in Medicine
  67. Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19
    Paulina Kapłonek, Deniz Cizmeci, Jessica Shih-Lu Lee, Sally A. Shin, Stephanie Fischinger, Philipe Gobeil, Stéphane Pillet, Nathalie Charland, Brian J. Ward, Galit Alter · 2023 · npj Vaccines
  68. Surging COVID-19 in Bangladesh driven by B.1.351 variant
    Eric Brum, Senjuti Saha, Ayesha Sania, Arif Mohammad Tanmoy, Yogesh Hooda, Afroza Akter Tanni, Sharmistha Goswami, Syed Muktadir Al Sium, Mohammad Saiful Islam Sajib, Roly Malaker et al. · 2021 · medRxiv
  69. Can proteomics-based approaches further help COVID-19 prevention and therapy?
    Vijay Kumar · 2021 · Expert Review of Proteomics
  70. Severity and inpatient mortality of COVID-19 pneumonia from Beta variant infection: a clinical cohort study in Cape Town, South Africa
    Linda Boloko, Aimee Lifson, Francesca Little, Timothy J. de Wet, Nectarios Papavarnavas, Gert J.K. Marais, Marvin Hsiao, Michael-John Rosslee, Deelan Doolabh, Arash Iranzadeh et al. · 2021 · medRxiv
  71. Clinical grade ACE2 effectively inhibits SARS-CoV-2 Omicron infections
    Vanessa Monteil, Stéphanie Devignot, Jonas Klingström, Charlotte Thålin, Max J. Kellner, Wanda Christ, Sebastian Havervall, Stefan Mereiter, Sylvia Knapp, Núria Montserrat et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  72. SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing antibodies than BA.1
    Simone I. Richardson, Thopisang P. Motlou, Mieke A. van der Mescht, Bronwen E. Lambson, Josie Everatt, Daniel Gyamfi Amoako, Anne von Gottberg, Nicole Wolter, Zelda de Beer, Talita Roma de Villiers et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  73. Human-to-dog Transmission of SARS-CoV-2 Lota Variant: Should COVID-19 Patients Avoid Close Contact with their Pets During Illness?
    Ricardo Rivero, Evelin Garay, Yesica Botero, Hector Serrano-Coll, Bertha Gastelbondo, Marina Muñoz, Nathalia Ballesteros, Sergio Castañeda, Luz Helena Patiño, Juan David Ramirez et al. · 2021 · Research Square
  74. 501Y.V2 spike protein resists the neutralizing antibody in atomistic simulations
    Sơn Tùng Ngô · 2022 · Computational Biology and Chemistry
  75. Looking at COVID-19 from a Systems Biology Perspective
    Emily Samuela Turilli-Ghisolfi, Marta Lualdi, Mauro Fasano · 2022 · Biomolecules
  76. Vaccination against SARS-CoV-2 should be included in childhood vaccination programs
    Eskild Petersen, Philippe Buchy · 2021 · International Journal of Infectious Diseases
  77. Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants
    Akira Takagi, Masanori Matsui · 2021 · Microbiology Spectrum
  78. Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice
    Juan Shi, Xiaoxiao Jin, Yan Ding, Xiaotao Kelvin Liu, Anran Shen, Yandan Wu, Min Peng, Chuanlai Shen · 2021 · Vaccines
  79. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
    Leo Hanke, Hrishikesh Das, Daniel J. Sheward, Laura Perez Vidakovics, Egon Urgard, Ainhoa Moliner-Morro, Changil Kim, Vivien Karl, Alec P. Pankow, Natalie L Smith et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  80. SARS-CoV-2 variants of concern: the knowns and unknowns
    Richard John Lessells · 2021 · Anaesthesia Critical Care & Pain Medicine
  81. Memory B cells control SARS-CoV-2 variants upon mRNA vaccination of naive and COVID-19 recovered individuals
    Aurélien Sokal, Giovanna Barba Spaeth, Ignacio Fernández, Matteo Broketa, Imane Azzaoui, Andrea de La Selle, Alexis Vandenberghe, Slim Fourati, Anaïs Roeser, Annalisa Meola et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  82. The importance of time post-vaccination in determining the decrease in vaccine efficacy against SARS-CoV-2 variants of concern
    Yinon M. Bar‐On, Εlad Noor, Noam Gottlieb, Alex Sigal, Ron Milo · 2021 · medRxiv
  83. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.
    Natasha M. Clark, S. Janaka, William Hartman, S. Stramer, E. Goodhue, J. Weiss, David T. Evans, J. Connor · 2021 · bioRxiv
  84. B.1.617.3 SARS CoV-2 spike E156G/Δ157-158 mutations contribute to reduced neutralization sensitivity and increased infectivity
    Tarun Kumar Mishra, Garima Joshi, Atul Kumar, Rishikesh Dalavi, Pankaj Pandey, Sanjeev Shukla, Ram Kumar Mishra, Ajit G. Chande · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  85. Insights into the limited global spread of the immune evasive SARS-CoV-2 variant Mu
    Mary E. Petrone, Carolina Gonçalves de Oliveira Lucas, Bridget L. Menasché, Mallery I. Breban, Inci B. Yildirim, Melissa Campbell, Saad B. Omer, Albert Icksang Ko, Nathan D. Grubaugh, Akiko Iwasaki et al. · 2022 · medRxiv
  86. Beta infection combined with Pfizer BNT162b2 vaccination leads to broadened neutralizing immunity against Omicron
    Sandile Cele, Mallory P. Bernstein, Farina Karim, Khadija Khan, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy, Gila Lustig, Natasha Samsunder, Matilda Mazibuko et al. · 2022 · medRxiv
  87. Humoral waning kinetics against SARS-CoV-2 is dictated by disease severity and vaccine platform
    Xin Tong, Benjamin P. Kellman, María José Avendaño, Maanasa Mendu, Jeff C. Hsiao, Eileen F. Serrano, Tamara García‐Salum, Nicolás A. Muena, Catalina Pardo‐Roa, Mauricio Morales et al. · 2024 · medRxiv
  88. RETRACTED: Towards sustainable development: Examining renewable energy consumption in E−7 countries
    Xi Chen, Saif Ur Rahman, Sehresh Abdullah, Shahzad Ali, Salman Khalid · 2024 · Heliyon · Retracted
  89. ARNLE model identifies prevalence potential of SARS-CoV-2 variants
    Yuqi Liu, Jing Li, Peihan Li, Kaiying Wang, Kaiying Wang, Jinhui Li, Lang Yang, Jiangfeng Liu, Leili Jia, Aiping Wu et al. · 2024 · Nature Machine Intelligence
  90. Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur
    Willi Fragcana Putra · 2022 · Jurnal Kedokteran Meditek
  91. Efficacy and Safety of Blood Derivative Therapy for Patients with COVID-19: A Systematic Review and Meta-Analysis
    Zhangcheng Fei, Zhongsheng Chen, Xi Du, Haijun Cao, Changqing Li · 2022 · Transfusion Medicine and Hemotherapy
  92. Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population
    Dipa Roy, Md. Mosfequr Rahman, A. S. Chaity, M. Reza, A. Haque · 2022 · Scientific Reports
  93. A structural perspective on the evolution of viral/cellular macromolecular complexes within the arenaviridae family of viruses
    Ron Diskin · 2023 · Current Opinion in Structural Biology
  94. Risk Factors and Drug Efficacy for Severe Illness in Hemodialysis Patients Infected with the Omicron Variant of COVID-19
    Wu Shui Yan, Lingling He, Yongping Guo, Niansong Wang · 2023 · Kidney & Blood Pressure Research
  95. Development of a novel medium throughput flow-cytometry based micro-neutralisation test for SARS-CoV-2 with applications in clinical vaccine trials and antibody screening
    Sophie R O’Reilly, Grace Kenny, Tamara Alrawahneh, Nathan Francois, Lili Gu, Matthew Angeliadis, Valentin de Masson d’Autume, Alejandro Garcia Leon, Eoin R. Feeney, Obada Yousif et al. · 2023 · PLoS ONE
  96. Immune dynamics of SARS-CoV-2 virus evolution
    Madhura Kamat, Vishakha Kurlawala, Geetanjali Ghosh, Radhika Vaishnav · 2022 · International Journal of Molecular and Immuno Oncology
  97. Environmental Health Perspectives on the Emergence and Re-Emergence of Infectious Diseases, Geopolitics and Gain of Function Research
    Chrysanthus Chukwuma · 2021 · Journal of Biomedical Research & Environmental Sciences
  98. Infectivity and antigenicity of pseudoviruses with high-frequency mutations of SARS-CoV-2 identified in Portugal
    Haixin Wang, Li Zhang, Zi-teng Liang, Jianhui Nie, Jia-jing Wu, Qian-qian Li, Ruxia Ding, Yue Zhang, Guoqing Chen, Youchun Wang et al. · 2022 · Archives of Virology
  99. Comparison of the immunogenicity of nasal‐spray rVSV vector, adenovirus vector, and inactivated COVID‐19‐based vaccines in rodent models
    Yuhang Zhang, Jiandong Liu, Hongyue Li, Fei Yuan, Congli Jiang, Tianle Cang, Kelei Li, Qiang Hu, Jiankai Liu, Aihua Zheng · 2023 · Journal of Medical Virology
  100. SARS-CoV-2 outbreak in a nursing home after vaccination with BNT162b2: A role for the quantification of circulating antibodies
    Jordi Cámara, Aída González-Díaz, Irene Barrabeig, Miguel Fernández-Huerta, Laura Calatayud, Jordí Niubó, Sara Martí, M.Á. Domínguez, Carmen Ardanuy · 2022 · Vaccine